DOCSLIB.ORG

Molsidomine for the Prevention of Vasospasm-Related Delayed

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Molsidomine for the Prevention of Vasospasm-Related Delayed CLINICAL ARTICLE J Neurosurg 124:51–58, 2016 Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study Angelika Ehlert, MD,1 Christoph Schmidt, MD,2 Johannes Wölfer, MD,3 Gerd Manthei, MD,1 Andreas H. Jacobs, MD,4 Roland Brüning, MD,5 Walter Heindel, MD,6 E. Bernd Ringelstein, MD,7 Walter Stummer, MD,3 Ryszard M. Pluta, MD,8 and Volker Hesselmann, MD6,9 1Department of Neurosurgery, Asklepios Hospital St. Georg, Hamburg; Departments of 2Anästhesiology, Intensive Care and Pain Medicine, 3Neurosurgery, 6Radiology, and 7Neurology, University Hospital Münster; 4European Institute of Molecular Imaging, Münster; 5Department of Radiology, Asklepios Hospital Barmbek, Hamburg; 9Asklepios Hospital Hamburg North, Hamburg, Germany; and 8Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland OBJECTIVE Delayed ischemic neurological deficits (DINDs) and cerebral vasospasm (CVS) are responsible for a poor outcome in patients with aneurysmal subarachnoid hemorrhage (SAH), most likely because of a decreased availability of nitric oxide (NO) in the cerebral microcirculation. In this study, the authors examined the effects of treatment with the NO donor molsidomine with regard to decreasing the incidence of spasm-related delayed brain infarctions and improving clinical outcome in patients with SAH. METHODS Seventy-four patients with spontaneous aneurysmal SAH were included in this post hoc analysis. Twenty- nine patients with SAH and proven CVS received molsidomine in addition to oral or intravenous nimodipine. Control groups consisted of 25 SAH patients with proven vasospasm and 20 SAH patients without. These patients received ni- modipine therapy alone. Cranial computed tomography (CCT) before and after treatment was analyzed for CVS-related infarcts. A modified National Institutes of Health Stroke Scale (mNIHSS) and the modified Rankin Scale (mRS) were used to assess outcomes at a 3-month clinical follow-up. RESULTS Four of the 29 (13.8%) patients receiving molsidomine plus nimodipine and 22 of the 45 (48%) patients receiving nimodipine therapy alone developed vasospasm-associated brain infarcts (p < 0.01). Follow-up revealed a me- dian mNIHSS score of 3.0 and a median mRS score of 2.5 in the molsidomine group compared with scores of 11.5 and 5.0, respectively, in the nimodipine group with CVS (p < 0.001). One patient in the molsidomine treatment group died, and 12 patients in the standard care group died (p < 0.01). CONCLUSIONS In this post hoc analysis, patients with CVS who were treated with intravenous molsidomine had a sig- nificant improvement in clinical outcome and less cerebral infarction. Molsidomine offers a promising therapeutic option in patients with severe SAH and CVS and should be assessed in a prospective study. http://thejns.org/doi/abs/10.3171/2014.12.JNS13846 KEY WORDS subarachnoid hemorrhage; molsidomine; CVS; DIND; vasospasm; NO; vascular disorders ABBREVIATIONS ACA = anterior cerebral artery; BA = basilar artery; BP = blood pressure; CBF = cerebral blood flow; CCT = cranial computed tomography; CVS = cerebral vasospasm; DIND = delayed ischemic neurological deficit; DSA = digital subtraction angiography; GCS = Glasgow Coma Scale; HES = hydroxyethyl starch; HH = Hunt and Hess; ICA = internal carotid artery; ICP = intracranial pressure; MAP = mean arterial blood pressure; MCA = middle cerebral artery; mNIHSS = modified National Institutes of Health Stroke Scale; mRS = modified Rankin Scale; MTG = molsidomine treatment group; NO = nitric oxide; SAH = subarachnoid hemorrhage; STG = standard therapy group; TCD = transcranial Doppler; VA = vertebral artery. SUBMITTED May 5, 2013. ACCEPTED December 29, 2014. INCLUDE WHEN CITING Published online July 10, 2015; DOI: 10.3171/2014.12.JNS13846. DISCLOSURES The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. ©AANS, 2016 J Neurosurg Volume 124 • January 2016 51 Unauthenticated | Downloaded 09/30/21 12:30 AM UTC A. Ehlert et al. P to 50% of patients suffering from subarachnoid Methods hemorrhage (SAH) develop delayed cerebral in- Patients farction and persistent neurological deficits. In up Uto 25% of cases, delayed strokes are responsible for severe Seventy-four consecutive patients with spontaneous disabilities,9,16 and approximately 75% of patients with aneurysmal SAH (age 16−86 years; mean 54.5 years, SD SAH experience persistent cognitive or mental deficits. 14.7) had been admitted to the intensive care unit of the Depending on the selection of patients, only a minority of University Hospital Münster, Germany, between Janu- survivors recover to a normal quality of life or return to ary 2008 and September 2009. All patients were treated work (6%–60%).1,24 with nimodipine. Twenty-nine consenting patients with Since the implementation of nimodipine in 1983, no CVS received molsidomine in addition to the standard new therapeutic approach for vasospasm-associated de- nimodipine therapy when clinical deterioration was obvi- layed ischemic neurological deficits (DINDs) after SAH ous (molsidomine treatment group [MTG]). The control has achieved general acceptance. Only orally adminis- group receiving standard nimodipine therapy consisted tered nimodipine has been shown to decrease the risk of of 45 patients (standard therapy group [STG]). In this DIND or poor clinical outcome.2,9,16 Despite nimodipine STG, 25 patients had CVS but refused molsidomine ther- treatment, vasospasm-associated infarcts occur in 20%– apy (STG-CVS). Twenty patients presented without CVS 50% of patients with SAH, DINDs in 27%–37% of pa- (STG-noCVS; Fig. 1). Epidemiological characteristics of tients, and severe morbidity in 30%–40% of patients.9,13,17 the patient population are presented in Table 1. The loca- A favorable outcome has been reported in less than 10% tions of the aneurysms are presented in Table 2. of patients with DIND, and the majority of those patients To avoid the inclusion of death events due to reasons (62%) have a poor outcome (severe disability, coma, other than CVS, we excluded from evaluation 9 patients death).17 who died within the first 6 days after SAH because of gen- Arteriographic vasospasm is detected in approximately eralized brain edema, severe hypoxia, massive rebleeding, 60%–70% of patients after SAH, but not all of them de- or a relevant mass shift due to parenchymal hematoma or velop DINDs, possibly because of a sufficient collateral causes directly related to procedures. blood supply.9,16 On the other hand, cerebral vasospasm Within 24 hours of admission, the aneurysms were (CVS), as detected by transcranial Doppler (TCD) ultraso- treated by coil embolization and/or clipping. Patients nography or arteriography, is not present in every patient treated by coiling received aspirin (100 mg/day). In the with DINDs. In these cases, DINDs have been attributed MTG, 20 patients were treated with coil embolization, 6 to decreased blood flow through the microcirculation due patients were treated with clipping, and 3 patients received to a locally reduced availability of nitric oxide (NO).18,19 both clipping and coiling. In the STG, 31 patients were Thus, detectable CVS in the macrocirculation may facili- treated with coil embolization, 12 patients with clipping, tate the development of DINDs but is not necessarily its 1 patient with coiling and clipping, and 1 patient was not main cause. These findings suggest that the impact of ce- treated at all. rebral microcirculation on the development of DINDs and Thirty-six patients received the standard therapy with poor outcome has been underestimated.11,18,19 nimodipine 6 tablets × 60 mg/day orally or via feeding Recently, this concept was further supported by results tube. Thirty-eight patients with deteriorated intestinal ab- of the CONSCIOUS 1–3 trials, which treated CVS pa- sorption received intravenous nimodipine 1–2 mg/hr in tients with endothelin receptor antagonists, and a newly the first days after SAH. TCD ultrasonography was per- published randomized trial investigating the therapeutic formed daily and included mean velocity measurements effect of cilostazol, an inhibitor of phosphodiesterase 3.26 of the internal carotid artery (ICA), the middle cerebral TCD ultrasonography-detectable vasospasm was signifi- artery (MCA), the anterior cerebral artery (ACA), the ver- cantly reduced, but the rate of DINDs and related infarcts tebral arteries (VAs), and the basilar artery (BA). CVS showed only a statistical trend toward improvement, and was diagnosed using 3 methods: 1) TCD ultrasonography, the clinical outcome was not altered,1,15,21 possibly because if the mean flow velocity in the ACA and the MCA was clazosentan acted only on the large conductive cerebral above 140 cm/sec or if it was > 120 cm/sec in the BA arteries. and VA, with a Lindegaard index > 3; 2) arteriography, For years, many treatments of DINDs and CVS after if narrowing > 50% of the vessel diameter, as compared SAH have been tried, including compounds with improved with initial values, was detected and DIND was argued; NO delivery. Several of them showed beneficial effects on or 3) the appearance of clinical symptoms within Day CVS, DIND, or clinical outcome.9,16,19,20 Unfortunately, 3–14, such as loss of consciousness or newly developed
Load more

Recommended publications
  • 2013 ESC Guidelines on the Management of Stable Coronary
    European Heart Journal Advance Access published August 30, 2013 European Heart Journal ESC GUIDELINES doi:10.1093/eurheartj/eht296 2013 ESC guidelines on the management of stable coronary artery disease The Task Force on the management of stable coronary artery disease of the European Society of Cardiology Task Force Members: Gilles Montalescot* (Chairperson) (France), Udo Sechtem* (Chairperson) (Germany), Stephan Achenbach (Germany), Felicita Andreotti (Italy), Chris Arden (UK), Andrzej Budaj (Poland), Raffaele Bugiardini (Italy), Filippo Crea Downloaded from (Italy), Thomas Cuisset (France), Carlo Di Mario (UK), J. Rafael Ferreira (Portugal), Bernard J. Gersh (USA), Anselm K. Gitt (Germany), Jean-Sebastien Hulot (France), Nikolaus Marx (Germany), Lionel H. Opie (South Africa), Matthias Pfisterer (Switzerland), Eva Prescott (Denmark), Frank Ruschitzka (Switzerland), Manel Sabate´ http://eurheartj.oxfordjournals.org/ (Spain), Roxy Senior (UK), David Paul Taggart (UK), Ernst E. van der Wall (Netherlands), Christiaan J.M. Vrints (Belgium). ESC Committee for Practice Guidelines (CPG): Jose Luis Zamorano (Chairperson) (Spain), Stephan Achenbach (Germany), Helmut Baumgartner (Germany), Jeroen J. Bax (Netherlands), He´ctor Bueno (Spain), Veronica Dean (France), Christi Deaton (UK), Cetin Erol (Turkey), Robert Fagard (Belgium), Roberto Ferrari (Italy), David Hasdai (Israel), Arno W. Hoes (Netherlands), Paulus Kirchhof (Germany/UK), Juhani Knuuti (Finland), Philippe Kolh (Belgium), Patrizio Lancellotti (Belgium), Ales Linhart (Czech Republic), Petros Nihoyannopoulos (UK), Massimo F. Piepoli (Italy), Piotr Ponikowski (Poland), Per Anton Sirnes (Norway), Juan Luis Tamargo (Spain), Michal Tendera (Poland), by guest on September 16, 2015 Adam Torbicki (Poland), William Wijns (Belgium), Stephan Windecker (Switzerland). Document Reviewers: Juhani Knuuti (CPG Review Coordinator) (Finland), Marco Valgimigli (Review Coordinator) (Italy), He´ctor Bueno (Spain), Marc J.
    [Show full text]
  • 심한 이형 협심증 환자에서 경구 Nitric Oxide Donor(Molsidomine) 효과
    Original Articles Korean Circulation J 1998;;;28(((9))):::1577-1582 심한 이형 협심증 환자에서 경구 Nitric Oxide Donor(Molsidomine) 효과 전남대학교병원 순환기내과,1 전남대학교 의과학연구소2 조장현1·정명호1,2·박우석1·김남호1·김성희1·김준우1 배 열1·안영근1·박주형1·조정관1,2·박종춘1,2·강정채1,2 The Effects of Oral Nitric Oxide Donor (((Molsidomine))) in Patients with Variant Angina Unresponsive to Conventional Anti-Anginal Drugs Jang Hyun Cho, MD1, Myung Ho Jeong, MD1,2, Woo Suk Park, MD1, Nam Ho Kim, MD1, Sung Hee Kim, MD1, Jun Woo Kim, MD1, Youl Bae MD1, Young Keun Ahn, MD1, Joo Hyung Park, MD1, Jeong Gwan Cho, MD1,2, Jong Chun Park, MD1,2 and Jung Chaee Kang, MD1,2 1Division of Cardiology, Chonnam University Hospital, Kwangju, 2The Research Institute of Medical Sciences, Chonnam National University, Kwangju, Korea ABSTRACT Background：We observed the changes of clinical characteristics after oral Molsidomine, a nitric oxide donor, in patients who have documented coronary artery spasm by ergonovine coronary angiogram and refractory to conventional anti-anginal therapy. Method：Molsidomine, oral nitric oxide donor, was administrated over 12 weeks in 20 patients (6 male, 14 female, 54±11.5 years) in order to observe the clinical effects in patients with coronary artery spasm unresponsive to nitrate and calcium channel blockers. Changes in the frequency of pain and sublingual nitroglycerin use, blood pressure, heart rate, side effects, electrocardiogram, and laboratory fin- dings were evaluated before and after Molsidomine therapy. Results：The frequencies of pain and sublingual nitroglycerin use were 3.9±0.9/week before treatment and decreased to 2.9±0.9/week at 4th week after the additional Molsidomine treatment (pre-treatment vs.
    [Show full text]
  • NITROGYLCERIN and ETHYLENE GLYCOL DINITRATE Criteria for a Recommended Standard OCCUPATIONAL EXPOSURE to NITROGLYCERIN and ETHYLENE GLYCOL DINITRATE
    CRITERIA FOR A RECOMMENDED STANDARD OCCUPATIONAL EXPOSURE TO NITROGYLCERIN and ETHYLENE GLYCOL DINITRATE criteria for a recommended standard OCCUPATIONAL EXPOSURE TO NITROGLYCERIN and ETHYLENE GLYCOL DINITRATE U.S. DEPARTMENT OF HEALTH, EDUCATION, AND WELFARE Public Health Service Center for Disease Control National Institute for Occupational Safety and Health June 1978 For »ale by the Superintendent of Documents, U.S. Government Printing Office, Washington, D.C. 20402 DISCLAIMER Mention of company name or products does not constitute endorsement by the National Institute for Occupational Safety and Health. DHEW (NIOSH) Publication No. 78-167 PREFACE The Occupational Safety and Health Act of 1970 emphasizes the need for standards to protect the health and provide for the safety of workers occupationally exposed to an ever-increasing number of potential hazards. The National Institute for Occupational Safety and Health (NIOSH) evaluates all available research data and criteria and recommends standards for occupational exposure. The Secretary of Labor will weigh these recommendations along with other considerations, such as feasibility and means of implementation, in promulgating regulatory standards. NIOSH will periodically review the recommended standards to ensure continuing protection of workers and will make successive reports as new research and epidemiologic studies are completed and as sampling and analytical methods are developed. The contributions to this document on nitroglycerin (NG) and ethylene glycol dinitrate (EGDN) by NIOSH staff, other Federal agencies or departments, the review consultants, the reviewers selected by the American Industrial Hygiene Association, and by Robert B. O ’Connor, M.D., NIOSH consultant in occupational medicine, are gratefully acknowledged. The views and conclusions expressed in this document, together with the recommendations for a standard, are those of NIOSH.
    [Show full text]
  • Treatment of Children with Pulmonary Hypertension. Expert Consensus Statement on the Diagnosis and Treatment of Paediatric Pulmonary Hypertension
    Pulmonary vascular disease ORIGINAL ARTICLE Heart: first published as 10.1136/heartjnl-2015-309103 on 6 April 2016. Downloaded from Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK Georg Hansmann,1 Christian Apitz2 For numbered affiliations see ABSTRACT administration (oral, inhaled, subcutaneous and end of article. Treatment of children and adults with pulmonary intravenous). Additional drugs are expected in the Correspondence to hypertension (PH) with or without cardiac dysfunction near future. Modern drug therapy improves the Prof. Dr. Georg Hansmann, has improved in the last two decades. The so-called symptoms of PAH patients and slows down the FESC, FAHA, Department of pulmonary arterial hypertension (PAH)-specific rates of clinical deterioration. However, emerging Paediatric Cardiology and medications currently approved for therapy of adults with therapeutic strategies for adult PAH, such as Critical Care, Hannover PAH target three major pathways (endothelin, nitric upfront oral combination therapy, have not been Medical School, Carl-Neuberg- fi Str. 1, Hannover 30625, oxide, prostacyclin). Moreover, some PH centres may use suf ciently studied in children. Moreover, the com- Germany; off-label drugs for compassionate use. Pulmonary plexity of pulmonary hypertensive vascular disease [email protected] hypertensive vascular disease (PHVD) in children is (PHVD) in children makes the selection of appro- complex, and selection of appropriate therapies remains priate therapies a great challenge far away from a This paper is a product of the fi writing group of the European dif cult. In addition, paediatric PAH/PHVD therapy is mere prescription of drugs.
    [Show full text]
  • Cardiovascular Implications in the Use of PDE5 Inhibitor Therapy
    International Journal of Impotence Research (2004) 16, S20–S23 & 2004 Nature Publishing Group All rights reserved 0955-9930/04 $30.00 www.nature.com/ijir Cardiovascular implications in the use of PDE5 inhibitor therapy DH Maurice* Department of Pharmacology & Toxicology, Queen’s University at Kingston, Kingston, ON, Canada Cardiovascular smooth muscle cells (SMCs) exist as resting or activated cells. Resting SMCs produce contractile proteins and are nearly transcriptionally inactive; activated SMCs are transcriptionally active and are involved in pathological processes such as atherosclerosis. Soluble guanylate cyclase, protein kinase G, and protein kinase A are present in SMCs, but their levels can be decreased in activated cells. Phosphodiesterase 3 (PDE3) activity is abundant in cardiovascular tissues; both PDE3A and PDE3B are involved in cyclic adenosine monophosphate (cAMP) hydrolysis in these tissues. Cyclic-AMP-hydrolyzing PDE activities are altered during the phenotypic transition of SMCs from the resting to the activated phenotype. Similar changes have been observed in cyclic guanosine monophosphate cGMP-hydrolyzing PDEs, although the impact of these alterations on PDE5 inhibitor-mediated effects requires further study. This report presents the changes in PDE expression that accompany phenotypic modulation of SMCs and discusses the potential impact of these events on PDE5-mediated cell functions. International Journal of Impotence Research (2004) 16, S20–S23. doi:10.1038/sj.ijir.3901210 Keywords: phosphodiesterase; smooth muscle cells; cyclic AMP; cyclic GMP; protein kinase Introduction Quiescent/resting SMCs, normally present in healthy blood vessels that perfuse most organs, contract and relax in response to pulsatile differ- In addition to physiologically based differences in ences in the blood flow and in response to the the expression of individual phosphodiesterases pharmacologic and physiologic stimuli.
    [Show full text]
  • NCX-4040, a Unique Nitric Oxide Donor, Induces Reversal of Drug-Resistance in Both ABCB1- and ABCG2-Expressing Multidrug Human Cancer Cells
    cancers Article NCX-4040, a Unique Nitric Oxide Donor, Induces Reversal of Drug-Resistance in Both ABCB1- and ABCG2-Expressing Multidrug Human Cancer Cells Birandra K. Sinha 1,*, Lalith Perera 2 and Ronald E. Cannon 1 1 Laboratory of Toxicology and Toxicokinetic, National Cancer Institute at National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA; [email protected] 2 Laboratory of Genome Integrity and Structural Biology, National Institute of Environmental Health Sciences, Research Triangle Park, NC 27709, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-984287-3382 Simple Summary: Development of resistance to chemotherapeutics during the treatment of human cancers is a serious problem in the clinic, resulting in a poor treatment outcome and survival. It is believed that overexpression of ABC efflux proteins (e.g., P-gp/ABCB1, BCRP/ABCG2 and MRP/ABCC1) on the tumor cell membrane is one of the main mechanisms for this clinical resistance. Our recent studies indicate that nitric oxide (NO), inhibits ATPase functions of ABC transporters, resulting in reversal of resistance to various anticancer drugs. In this study we have found that nitric oxide and/or active metabolite (s) generated from NCX4040, a nitric oxide donor, inhibited ABC transporter activities by inhibiting their ATPase functions, causing reversal of both adriamycin and topotecan resistance in human MDR tumor cells. We also found that nitric oxide and/or metabolites of NCX4040 significantly enhanced drug accumulations in MDR tumor cells. These Citation: Sinha, B.K.; Perera, L.; studies strongly suggest that tumor specific nitric oxide donors that deliver high amounts of nitric Cannon, R.E.
    [Show full text]
  • Molsidomine, Nicorandil, Trimetazidine의 안전성 관련 체계적 고찰
    한국임상약학회지 제26권 제2호 Korean Journal of Clinical Pharmacy Korean J Clin Pharm, Vol. 26, No. 2, 2016 Official Journal of Korean College of Clinical Pharmacy Original Article Available online at http://www.kccp.or.kr pISSN: 1226-6051 Molsidomine, Nicorandil, Trimetazidine의 안전성 관련 체계적 고찰 정경혜1·김은경2* 1중앙대학교 약학대학, 2서울대학교 약학대학 (2016년 4월 19일 접수·2016년 5월 20일 수정·2016년 5월 20일 승인) A Systematic Review on Drug Safety for Molsidomine, Nicorandil and Trimetazidine Kyeong Hye Jeong1 and Euni Lee2* 1College of Pharmacy, Chung-Ang University, Seoul 06974, Republic of Korea 2College of Pharmacy, Seoul National University, Seoul 08826, Republic of Korea (Received April 19 2016·Revised May 20 2016·Accepted May 20 2016) ABSTRACT Background: Ischemic heart disease is the most common type of heart disease and an important cause of death in Korea. Among marketed anti-anginal medications, molsidomine, nicorandil, and trimetazidine are approved in Korea with unique mechanism of actions. As these drugs are not approved by the US Food and Drug Administration, the access to the up-to-dated and comprehensive safety-related information has been less than optimal from drug information resources used by Korean pharmacists. Methods: A systematic review was conducted using Embase and Korean manuscripts to compile safety updates for these medications. Out of 418 articles from keyword searches, 52 studies were reviewed in full to compare adverse effects (AEs) with the approved package inserts (PI). Results: Molsidomine related adverse effects were mostly mild or moderate, but anxiety, palpitation, epigastric pain, and sexual potency reduction were additional AEs found from the review not listed in PI.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,037,346 Doherty, Jr
    US006037346A United States Patent (19) 11 Patent Number: 6,037,346 Doherty, Jr. et al. (45) Date of Patent: Mar. 14, 2000 54) LOCAL ADMINISTRATION OF WO 96/16644 6/1996 WIPO. PHOSPHODESTERASE INHIBITORS FOR THE TREATMENT OF ERECTLE OTHER PUBLICATIONS DYSFUNCTION Bush et al. (1992), “Nitric Oxide is a Potent Relaxant of 75 Inventors: Paul C. Doherty, Jr., Cupertino, Calif.; Human and Rabbit Corpus Cavernosum.” The Journal of Virgil A. Place, Kawaihae, Hi.; Urology 147(6):1650–1655. William L. Smith, Mahwah, N.J. Doherty (1997), “Oral, Transdermal, and Transurethral Therapies for Erectile Dysfunction,” Male Infertility and 73 Assignee: Vivus, Inc., Mountain View, Calif. Dysfunction, Hellstron, ed., Chapter 33 (New York, New York: Springer-Verlag Hellstrom), pp. 452-467. 21 Appl. No.: 09/181,070 Rajfer et al. (1992), "Nitric Oxide as a Mediator of Relax ation of the Corpus CavernoSum in Response to Nonadren 22 Filed: Oct. 27, 1998 ergic, Noncholinergic Neurotransmission.” The New England Journal of Medicine 326(2):90-94. Related U.S. Application Data Taher et al. (1992), “Cyclic nucleotide phosphodiesterase 63 Continuation-in-part of application No. 08/958,816, Oct. 28, activity in human cavernous Smooth muscle and the effect of 1997, abandoned. various selective inhibitors,” International Journal of Impo tence Research (Supplement 2) 4:11. 51 Int. Cl." - A61K 31/50 Trigo-Rocha et al. (1993), “The Role of Cyclic Adenosine 52 U.S. Cl. .............................................................. 514/258 Monophosphate, Cyclic Guanosine Monophosphate, Endot 58 Field of Search ............................................... 514/258 helium and Nonadrenergic, Noncholinergic Neurotransmis sion in Canine Penile Erection.” The Journal of Urology 56) References Cited 149(4):872-877.
    [Show full text]
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices
    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
    [Show full text]
  • A Study of Vericiguat in Participants with Heart Failure with Reduced Ejection Fraction (Hfref) (MK-1242-001) (VICTORIA)
    A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001) (VICTORIA) SECONDARY IDENTIFICATION NUMBER MK-1242-001-04, VICTORIA; CT.gov: NCT02861534 FDA CLINICAL TRIAL REFERENCE (CTR) NUMBER 2016-CT0367 SCIENTIFIC TITLE A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) PROJECT DESCRIPTION This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF. NUHRA DETAILS Regime Classification Priority 2010 - 2016 Health Technology Development Drug Discovery and Development PROJECT DURATION Start Date Duration in Months Target Completion Date Actual Completion Date 2017-01-30 36 2020-01-30 2020-03-04 PROJECT STATUS Completed REASON FOR PROJECT PENDING/SUSPENSION/TERMINATION Unspecified IMPLEMENTING AGENCY (PRIMARY SPONSOR) Institution Classification Region LTO # Merck Sharp & Dohme (I.A.) LLC Private Business NCR CDRR-NCR-S-16 COOPERATING AGENCY (SECONDARY SPONSOR) Institution Classification Region LTO # No records Found. CONTRACT RESEARCH ORGANIZATION (CRO) INFORMATION Contact #s.: (+632) 8377534, (+632) 8377537, (+632) 8372071-80 loc. 2117, 2112 Saliksik Building, DOST Compound, Gen. Santos Ave., Bicutan Taguig City 1631 Philippines Page 1/6 Institution Classification Region LTO # No records Found.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • 1344 Cardiovascular Drugs
    1344 Cardiovascular Drugs Molsidomine is metabolised to linsidomine (p.1325), an active Moracizine Hydrochloride (BANM, rINNM) 2. Mehta AV, et al. Experience with moricizine HCl in children metabolite. with supraventricular tachycardia. Int J Cardiol 1996; 57: 31–5. Hidrocloruro de moracizina; Moracizine, Chlorhydrate de; 3. Geller JC, et al. Efficacy and safety of moricizine in the mainte- Carcinogenicity. Molsidomine tends to degrade into morpho- Moracizinhydroklorid; Moracizini Hydrochloridum; Morasitsiini- nance of sinus rhythm in patients with recurrent atrial fibrilla- line (even when protected from the light), a compound consid- hydrokloridi. tion. Am J Cardiol 2001; 87: 172–7. ered potentially carcinogenic. This finding led to the suspension Preparations 1 Морацизина Гидрохлорид of marketing of one molsidomine formulation; an earlier tempo- C H N O S,HCl = 464.0. USP 31: Moricizine Hydrochloride Tablets. rary suspension was related to evidence of carcinogenicity in 22 25 3 4 CAS — 29560-58-5. Proprietary Preparations (details are given in Part 3) some animals, although this has not been confirmed in humans. ATC — C01BG01. USA: Ethmozine†. 1. Anonymous. Corvaton Tropfen. Dtsch Apotheker Ztg 1989; 129 ATC Vet — QC01BG01. (49): VI. Pharmacopoeias. In Chin. and US. Myocardial infarction. Although intravenous nitrates (glycer- USP 31 (Moricizine Hydrochloride). A white to off-white crys- Moxisylyte Hydrochloride (BANM, rINNM) yl trinitrate or sodium nitroprusside) may be used in the manage- talline powder. Soluble in water and in alcohol. Store in airtight ment of acute myocardial infarction (p.1175), molsidomine and containers. Hidrocloruro de moxisilita; Moksisylyyttihydrokloridi; Moxisilita its active metabolite linsidomine (a nitric oxide donor) had no Clorhidrato; Moxisylyte, Chlorhydrate de; Moxisylythydroklorid; effect on mortality.1 Adverse Effects Moxisylyti Hydrochloridum; Moxisylytum Hydrochloridum; Thy- The most common adverse effects associated with moracizine moxamine Hydrochloride.
    [Show full text]